Business Wire

Revolutionary Metop-SGA1 Already Transmitting Instrument Data

2.9.2025 15:46:00 CEST | Business Wire | Press Release

Share

Less than three weeks after the launch of Metop Second Generation A1 (Metop-SGA1) on 13 August, the satellite is beaming data from two of its six instruments. The data, from the Microwave Sounder (MWS) and Radio Occultation Sounder (RO), are a first peek at the game-changing meteorological and climate insight that Metop-SGA1 will deliver.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250902768977/en/

Striking 24-hour image from MWS’s Channel 17 on 24 August. Besides Earth’s surface properties, this channel is also sensitive to convective clouds, shown as various filaments and banding structures over the oceans. For instance, the red swirl visible in the North Atlantic reflects the deep convective cloud system of Ex-hurricane Erin.

The satellite is the first to be deployed of the EUMETSAT Polar System – Second Generation, Europe’s groundbreaking polar-orbiting weather satellite programme. By augmenting Numerical Weather Prediction (NWP) models and providing essential observations of atmospheric composition and ocean parameters, Metop-SGA1 will help to protect the health and property of European citizens.

Metop-SGA1’s instruments are currently undergoing a complex and exhaustive commissioning process. Initial data from two of the spacecraft’s sounders has nonetheless already been received through the Svalbard Ground Station and processed at EUMETSAT.

The MWS is a microwave sounder that detects temperature, humidity, precipitation and ice cloud formation and features a twofold improvement in resolution compared with its predecessor. The instrument began sensing just one week after launch, and imagery from its Channel 2 data during the first scanning orbit clearly shows summer temperatures in Europe and sea ice around the Antarctic.

The Radio Occultation Sounder is a limb-sounding instrument that produces around 1,400 daily vertical profiles of temperature and humidity, along with electron density profiles in the ionosphere. The RO has a very high vertical resolution, enabling it to give detailed insight into the vertical structure of the atmosphere. RO data also helps in calibrating other remote sensing observations, as it is weather-independent and calibration-free. Temperature profiles from the RO from 20 August demonstrate how the instrument may enhance existing forecasts in the future.

Both the MWS and RO will provide inputs of unprecedented precision for NWP. While these early signals show that progress is continuing at pace, the data is not yet operationally qualified, and the commissioning of Metop-SGA1 is expected to require months of thorough testing and calibration before any data are released to Member State meteorological services or other users.

Phil Evans, EUMETSAT Director-General, said: “Receiving these first data so quickly is a thrilling achievement for EUMETSAT, particularly considering the technological sophistication of Metop-SGA1 and its payload. In collaboration with the European Space Agency (ESA) and our European industry partners, EUMETSAT teams are working intensely to render all the satellite’s instruments operational, and the fact that data is already flowing seamlessly from the MWS and the RO shows that we are firmly on the right track to having powerful, validated products ready for our user community in the planned timeframe.”

Simonetta Cheli, ESA’s Director of Earth Observation Programmes, said, “These first glimpses of data are extremely encouraging, and I want to thank all the teams who have contributed – both to developing the mission as a whole and to operating and commissioning Metop-SGA1 in orbit.

“This is a major undertaking: six satellites in total, flying in successive pairs and delivering critical data for at least the next 20 years. While we closely monitor Metop-SGA1’s early performance, we are already in the final stages of preparing its companion, Metop-SGB1, for launch next year.

For further updates on Metop-SGA1, visit EUMETSAT’s launch hub, which features news, interviews, and insights into the satellite’s journey. Details of the payloads on both EPS-SG satellites can be found on the dedicated Metop-SG instruments page.

Find all relevant information, biographies of speakers, videos and testimonials on our Metop-SGA1 press page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250902768977/en/

Contacts

Media Relations EUMETSAT:
Tel. : +49 6151 807 7320
Email: press@eumetsat.int
www.eumetsat.int -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.eumetsat.in
t%2F&esheet=54316589&newsitemid=20250902768977&lan=en-US&anchor=www.eumetsat.int
&index=5&md5=2cefc97d6848f358c844ce5d0618c424

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye